Close Menu

NEW YORK (GenomeWeb) – IncellDx today announced it received CE marking for it flow cytometry-based test for human papillomavirus.

The company also announced the launch of the test, which combines the quantification of oncogene mRNA overexpression, proliferation, and aneuploidy in one high-throughput assay. It quantifies the E6/E7 mRNA overexpression by RNA in situ hybridization and combines it with cell cycle DNA, which quantifies proliferation, which IncellDx said is a hallmark of transformation to cancer.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A new blood test might be able to detect the presence of some 50 cancers, according to New Scientist.

Undark looks into how coronavirus-related shutdowns are affecting field researchers.

In PNAS this week: strategies to design DNA oligonucleotide probes for bacteria, Vibrio cholerae evolution in Haiti, and more.

NPR reports that graduate students in the US are helping with SARS-CoV-2 testing.